Podoplanin (PDPN), a type I transmembrane sialoglycoprotein, is expressed on normal renal podocytes, pulmonary type I alveolar cells, and lymphatic endothelial cells. Increased expression of PDPN in cancers is associated with poor prognosis and hematogenous metastasis through interactions with C-type lectin-like receptor 2 (CLEC-2) on platelets. We previously reported a novel PMab-48 antibody, which is an anti-dog PDPN (dPDPN) monoclonal antibody (mAb) recognizing PDPN expressed in lymphatic endothelial cells. However, the binding epitope of PMab-48 is yet to be clarified. In this study, an enzyme-linked immunosorbent assay and flow cytometry were used to investigate epitopes of PMab-48. The results revealed that the critical epitope of PMab-48 comprises Asp29, Asp30, Ile31, Ile32, and Pro33 of dPDPN.
Introduction
P odoplanin (PDPN) is expressed in normal tissues such as renal podocytes, pulmonary type I alveolar cells, lymphatic endothelial cells, chondrocytes, myofibroblasts, and mesothelial cells.
(1) However, higher expression of PDPN has been observed in different tumor types, including squamous cell carcinoma, (2) melanoma, (3) glioblastoma, (4) and mesothelioma. (5) Recent clinical studies have provided evidence of associations between increased PDPN expression, poor prognosis, and cancer metastasis, (6) indicating that the establishment and production of anti-PDPN monoclonal antibodies (mAbs) are necessary for developing novel therapeutic strategies against cancer development and progression to metastasis. (7) Dog podoplanin (dPDPN) was first reported as gp40. (8) Recently, we developed two mAbs, PMab-38 (2, 3, 9) and PMab-48, (10) both of which specifically recognize dPDPN. Tyr67 and Glu68 were determined to be the critical features of the epitope of PMab-38. (11) Using point mutants of dPDPN, the present study aimed to investigate the epitope of PMab-48 by enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
Materials and Methods

Cell lines
CHO-K1 cells were transfected with the dPDPN-MAP tag plasmid using Lipofectamine LTX (Thermo Fisher Scientific, Inc., Waltham, MA). (9) CHO/dPDPN cells were cultured in an RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan), supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Inc., Waltham, MA), 100 U/mL penicillin, 100 mg/mL streptomycin, and 25 mg/mL amphotericin B (Nacalai Tesque, Inc.), and incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air.
Enzyme-linked immunosorbent assay
Synthesized dPDPN peptides (PEPScreen; Sigma-Aldrich Corp., St. Louis, MO) were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific, Inc.) at 5 mg/mL for 30 minutes. After blocking with SuperBlock T20 (phosphatebuffered saline [PBS]) Blocking Buffer (Thermo Fisher Scientific, Inc.), the plates were incubated with purified PMab-48 (10 mg/mL), followed by a 1:2000 dilution of peroxidaseconjugated anti-mouse IgG (Agilent Technologies, Inc., Santa Clara, CA). The enzymatic reaction was conducted using 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific, Inc.). Optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories, Inc., Berkeley, CA). These reactions were performed at 37°C with a total sample volume of 50-100 mL.
Flow cytometry
Cells were harvested after brief exposure to 0.25% trypsin/ 1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin in PBS, the cells were treated with PMab-48 (10 mg/mL) or PMab-48 (10 mg/mL) plus peptides (10 mg/mL) for 30 minutes at 4°C, followed by treatment with Alexa Fluor 488-conjugated antimouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA). Fluorescence data were acquired using the cell analyzer SA3800 (Sony Corp., Tokyo, Japan).
Results
We previously developed a novel PMab-48 mAb that exhibits high specificity and sensitivity against dPDPN and is highly suitable for detection of lymphatic endothelial cells in immunohistochemical analysis. (10) PMab-48 can be used to detect dPDPN expressed by squamous cell carcinomas. (10) These findings suggest that PMab-48 epitope mapping could be a promising target for PDPN-based diagnosis and cancer therapy.
In this study, we synthesized a series of point mutants of dPDPN peptides from the 26th to the 40th amino acid (Table 1) . Using ELISA, PMab-48 detected V26A, R27A, P28A, G34A, V35A, E36A, D37A, S38A, V39A, and V40A; in contrast, PMab-48 did not react with D29A, D30A, I31A, I32A, or P33A, indicating that the DDIIP sequence is a critical epitope of PMab-48.
Next, we performed a blocking assay using flow cytometry. PMab-48 reacted with the CHO/dPDPN cell line (Fig. 1) . This reaction was completely neutralized by the wild-type peptide (VRPDDIIPGVEDSVV) and V35A; in contrast, D29A, D30A, I31A, I32A, and P33A did not block the reaction of PMab-48 with CHO/dPDPN, indicating that the DDIIP sequence is a critical epitope of PMab-48 (Fig. 2) .
FIG. 1.
Flow cytometry using PMab-48 and point mutants of dPDPN. PMab-48 or PMab-48 + peptides (WT, D29A, D30A, I31A, I32A, P33A, or V35A) were treated with CHO/dPDPN cells for 30 minutes at 4°C, followed by addition of secondary antibodies. dPDPN, dog podoplanin; WT, wild type; gray peak, negative control. 
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Previously, a critical epitope of another anti-dPDPN mAb, PMab-38, was determined to comprise Tyr67 and Glu68, (11) indicating that epitopes of PMab-48 and PMab-38 are different (Fig. 2) . PMab-48 reacted with lymphatic endothelial cells in immunohistochemistry, (10) although PMab-38 did not, (9) demonstrating that the N-terminal region is a more adequate epitope for detecting dPDPN of lymphatic endothelial cells probably because N-terminus might not be O-glycosylated.
In contrast, PMab-38 showed cancer specificity in immunohistochemistry using canine tissues (2) in the same pattern with anti-human PDPN (hPDPN) cancer-specific mAbs, such as LpMab-2 (7, 13) and LpMab-23. (6, 14, 15) We previously showed that Thr55-Leu64 peptide of hPDPN, especially O-glycan attached in Thr55 and Ser56 of hPDPN, is a critical epitope of LpMab-2. (7) We further showed that Gly54-Leu64 peptide of hPDPN is a critical epitope of LpMab-23. (15) The epitope of PMab-38 for dPDPN is similar to those of LpMab-2 and LpMab-23 for hPDPN. Therefore, this kind of epitope mapping provides important evidence for clinical application of anti-PDPN mAbs.
